文献速递银屑病与炎症性皮肤病

依奇珠单抗持续给药与间断治疗银屑病的整合分析

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-03-31

基于UNCOVER-1和UNCOVER-2两项3期试验的整合数据,评估中重度银屑病患者持续使用依奇珠单抗与中断后复发再治疗的结局。持续治疗至60周可维持高水平PASI和sPGA应答,中断治疗者多数在60周内复发,中位复发时间约20周,再治疗24周后多数患者可重新获得应答。

要点

  • 持续依奇珠单抗治疗至60周可维持高水平的PASI和sPGA应答。
  • 中断治疗者多数出现复发,中位复发时间约20周,与诱导剂量无关。
  • 复发后以IXEQ4W再治疗24周,多数患者可重新获得PASI 75和sPGA 0,1应答。

核心结论

  • 持续依奇珠单抗治疗至60周可维持高水平应答,中断治疗者多数复发,再治疗24周后多数可重新获得应答。

研究设计与样本

  • 整合UNCOVER-1和UNCOVER-2两项3期试验数据,共1226例治疗患者在第12周达到sPGA 0,1并进入维持期。

主要发现

  • 中断治疗者中IXEQ4W/PBO有157例(82.2%)、IXEQ2W/PBO有176例(83.4%)在60周时sPGA≥3,中位复发时间约20周。
  • 第60周持续治疗者维持高水平应答:IXEQ2W/IXEQ4W组PASI 75为90.0%,sPGA 0,1为81.9%(无应答者填补)。
  • 再治疗24周后IXEQ2W/PBO/IXEQ4W和IXEQ4W/PBO/IXEQ4W组分别有87.0%(107/123)和95.1%(97/102)重新获得PASI 75(观测值)。
  • 再治疗24周后上述两组分别有70.7%(104/147)和82.3%(107/130)重新获得sPGA 0,1(观测值)。
  • 持续治疗与再治疗患者的不良事件总体相当。

关键数值与推荐

  • 第12周达到sPGA 0,1者再随机至IXEQ4W、IXE每12周(未展示)或PBO。
  • 复发定义为sPGA≥3,再治疗为IXEQ4W持续24周。

临床怎么用

  • 中重度银屑病应优先持续使用依奇珠单抗以维持应答,中断后需监测复发并在复发后及时再治疗。

局限性

  • 为两项3期试验的整合分析,部分数据采用无应答者填补或观测值分析,再治疗数据非随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Continuous treatment is recommended for patients with moderate-to-severe psoriasis; however, treatment may need to be interrupted in routine clinical practice. OBJECTIVE: To assess outcomes in patients continuously treated with ixekizumab versus those who interrupted therapy and were subsequently retreated with ixekizumab (IXE). METHODS: This analysis used data pooled from two phase 3 trials, UNCOVER-1 and UNCOVER-2. Patients were randomized to placebo (PBO), IXE every 4 (Q4W) or IXE every 2 weeks (Q2W) for 12 weeks. Patients with a static Physician's Global Assessment (sPGA) 0, 1 at Week 12 were rerandomized to IXEQ4W, IXE every 12 weeks (not presented) or PBO. We examined outcomes in patients who were continuously treated (IXEQ2W/IXEQ4W; IXEQ4W/IXEQ4W) or withdrawn (IXEQ2W/PBO; IXEQ4W/PBO), and in patients who were withdrawn and retreated with IXEQ4W for 24 weeks after disease relapse (sPGA ≥3). RESULTS: A total of 1226 treated patients achieved an sPGA 0, 1 at Week 12 and entered the maintenance phase; of these patients, 402 and 416 were rerandomized to PBO and IXEQ4W, respectively. Among patients interrupting treatment, 157 (82.2%) of IXEQ4W/PBO and 176 (83.4%) of IXEQ2W/PBO had an sPGA ≥3 by Week 60; median time to relapse was approximately 20 weeks irrespective of induction dose. At Week 60, continuously treated patients maintained high levels of PASI and sPGA responses (90.0% PASI 75 IXEQ2W/IXEQ4W; 81.9% sPGA 0, 1 IXEQ2W/IXEQ4W, non-responder imputation). After 24 weeks of retreatment with IXEQ4W (IXEQ2W/PBO/IXEQ4W and IXEQ4W/PBO/IXEQ4W), 87.0% (107 of 123) and 95.1% (97 of 102) (observed), respectively, of patients recaptured PASI 75 and 70.7% (104 of 147) and 82.3% (107 of 130) (observed) recaptured an sPGA 0, 1. Overall, adverse events in continuously treated and retreated patients were comparable. CONCLUSION: High levels of response were sustained with continuous ixekizumab treatment through 60 weeks. Most patients who were withdrawn experienced disease relapse, and most of those patients recaptured response after 24 weeks of retreatment.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Papp KA, Sofen H, et al. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol. 2017. PMID: 28190255. doi:10.1111/jdv.14163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。